Metabolomics of beta-blockers

Carvedilol is a nonselective β-blocker with multiple properties, including antioxidant properties, α-adrenergic blocking effects and inhibitory effects on calcium channels. It has been used in the clinical treatment of hypertension and congestive heart failure. While it is known that each enantiomer...

Full description

Saved in:
Bibliographic Details
Main Author: Tan, Ian Yong Ming.
Other Authors: Chen Wei Ning, William
Format: Final Year Project
Language:English
Published: 2010
Subjects:
Online Access:http://hdl.handle.net/10356/39680
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Nanyang Technological University
Language: English
id sg-ntu-dr.10356-39680
record_format dspace
spelling sg-ntu-dr.10356-396802023-03-03T15:33:17Z Metabolomics of beta-blockers Tan, Ian Yong Ming. Chen Wei Ning, William School of Chemical and Biomedical Engineering DRNTU::Engineering::Chemical engineering::Biotechnology Carvedilol is a nonselective β-blocker with multiple properties, including antioxidant properties, α-adrenergic blocking effects and inhibitory effects on calcium channels. It has been used in the clinical treatment of hypertension and congestive heart failure. While it is known that each enantiomer of Carvedilol exhibits different pharmacological activity, their effects at the cellular level are not well understood. In order to better understand how each enantiomer affects cells, the metabolite profiles of vascular smooth muscle cells (A7r5) were analysed after incubating with S- and R-Carvedilol separately using GC-MS technology. 27 metabolites were shown to be commonly expressed in all the samples and of the 27 metabolites, 8 metabolites were identified to be of particular interest. These metabolites are lactic acid, alanine, succinic acid, 5-oxoproline and proline, spermidine, threonine and aspartic acid. These metabolites were closely related to the clinical effects of Carvedilol and the differences in the levels of metabolites, as analysed by GC-MS, further supported the known differences in the pharmacological effects of the two enantiomers. The results will lead to a better understanding of the metabolic pathway of Carvedilol and subsequently facilitate the development of novel drug applications utilising the special properties of Carvedilol. Bachelor of Engineering (Chemical and Biomolecular Engineering) 2010-06-02T09:00:31Z 2010-06-02T09:00:31Z 2010 2010 Final Year Project (FYP) http://hdl.handle.net/10356/39680 en Nanyang Technological University 51 p. application/pdf
institution Nanyang Technological University
building NTU Library
continent Asia
country Singapore
Singapore
content_provider NTU Library
collection DR-NTU
language English
topic DRNTU::Engineering::Chemical engineering::Biotechnology
spellingShingle DRNTU::Engineering::Chemical engineering::Biotechnology
Tan, Ian Yong Ming.
Metabolomics of beta-blockers
description Carvedilol is a nonselective β-blocker with multiple properties, including antioxidant properties, α-adrenergic blocking effects and inhibitory effects on calcium channels. It has been used in the clinical treatment of hypertension and congestive heart failure. While it is known that each enantiomer of Carvedilol exhibits different pharmacological activity, their effects at the cellular level are not well understood. In order to better understand how each enantiomer affects cells, the metabolite profiles of vascular smooth muscle cells (A7r5) were analysed after incubating with S- and R-Carvedilol separately using GC-MS technology. 27 metabolites were shown to be commonly expressed in all the samples and of the 27 metabolites, 8 metabolites were identified to be of particular interest. These metabolites are lactic acid, alanine, succinic acid, 5-oxoproline and proline, spermidine, threonine and aspartic acid. These metabolites were closely related to the clinical effects of Carvedilol and the differences in the levels of metabolites, as analysed by GC-MS, further supported the known differences in the pharmacological effects of the two enantiomers. The results will lead to a better understanding of the metabolic pathway of Carvedilol and subsequently facilitate the development of novel drug applications utilising the special properties of Carvedilol.
author2 Chen Wei Ning, William
author_facet Chen Wei Ning, William
Tan, Ian Yong Ming.
format Final Year Project
author Tan, Ian Yong Ming.
author_sort Tan, Ian Yong Ming.
title Metabolomics of beta-blockers
title_short Metabolomics of beta-blockers
title_full Metabolomics of beta-blockers
title_fullStr Metabolomics of beta-blockers
title_full_unstemmed Metabolomics of beta-blockers
title_sort metabolomics of beta-blockers
publishDate 2010
url http://hdl.handle.net/10356/39680
_version_ 1759853845429616640